Miyastenia Graviste Güncel Tedavi
Özet
Miyastenia gravis tedavisi, hastalığın klinik şiddeti, antikor durumu (AChR, MuSK, LRP4), timus patolojisi ve hastaya ait komorbiditelere göre bireyselleştirilebilir. Tedavinin temelini semptomatik, immünsupresif ve hedefe yönelik biyolojik ajanların kullanımı oluşturur. İlk basamakta asetilkolinesteraz inhibitörleri (özellikle piridostigmin) kullanılır ve çoğu hastada kas güçsüzlüğünde anlamlı düzelme sağlar. Yetersiz yanıt veya orta-ağır hastalıkta kortikosteroidler eklenir; uzun dönem yan etkileri azaltmak için steroid dışı immünsupresanlar (azatioprin, mikofenolat mofetil, siklosporin, metotreksat) tercih edilir. Timektomi, özellikle AChR antikor pozitif, jeneralize miyastenia gravis’te, uygun hastalarda uzun dönem remisyon oranlarını artırır. Miyastenik kriz durumunda ise plazmaferez veya intravenöz immünglobulin hızlı ve etkili tedavilerdir. Son yıllarda tedavide önemli bir gelişme, hedefe yönelik biyolojik ajanların kullanıma girmesidir. Kompleman inhibitörleri (eculizumab, ravulizumab) AChR antikor pozitif refrakter miyastenia gravis’te etkili bulunmuştur. FcRn inhibitörleri (efgartigimod, rozanolixizumab), dolaşımdaki patojenik IgG düzeylerini azaltarak hızlı ve belirgin klinik iyileşme sağlar ve güncel kılavuzlarda önemli yer edinmiştir. Güncel yaklaşım, erken tanı, doğru fenotipleme ve hedefe yönelik tedaviyle fonksiyonel iyileşme ve yaşam kalitesini en üst düzeye çıkarmayı amaçlamaktadır.
Referanslar
Tannemaat MR, Huijbers MG, Verschuuren JJGM. Chapter 17 - Myasthenia gravis—Pathophysiology, diagnosis, and treatment, Editor(s): Bruno Giometto, Sean J. Pittock, Handbook of Clinical Neurology, Elsevier, Volume 200, 2024, Pages 283-305, https://doi.org/10.1016/B978-0-12-823912-4.00026-8.
Punga AR, Maddison P, Heckmann JM, et al. Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022 Feb;21(2):176-188. doi: 10.1016/S1474-4422(21)00297-0. PMID: 35065040.
Huijbers MG, Marx A, Plomp JJ, et al. Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022 Feb;21(2):163-175. doi: 10.1016/S1474-4422(21)00357-4. PMID: 35065039.
Estephan EP, Baima JPS, Zambon AA. Myasthenia gravis in clinical practice. Arq Neuropsiquiatr. 2022 May;80(5 Suppl 1):257-265. doi: 10.1590/0004-282X-ANP-2022-S105. PMID: 35976295; PMCID: PMC9491427.
Plomp JJ. Trans-synaptic homeostasis at the myasthenic neuromuscular junction. Front Biosci (Landmark Ed). 2017 Mar 1;22(7):1033-1051. doi: 10.2741/4532. PMID: 28199191.
Binks SNM, Morse IM, Ashraghi M, et al. Myasthenia gravis in 2025: five new things and four hopes for the future. J Neurol. 2025 Feb 22;272(3):226. doi: 10.1007/s00415-025-12922-7. PMID: 39987373; PMCID: PMC11846739.
Verschuuren JJ, Palace J, Murai H, et al. Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. The Lancet Neurology, 2022; 21(2), 189-202. doi:10.1016/S1474-4422(21)00463-4
Thomsen, Jan Lykke Scheel et al. A population-based follow-up study of maximal muscle strength and mobility in patients with myasthenia gravis Neuromuscular Disorders. 2022; Volume 32, Issue 4, 305 - 312
Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology. 2016;87(4):419-425. doi:10.1212/WNL.0000000000002790
Gilhus NE, Andersen H, Andersen LK, et al. Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment. Eur J Neurol. 2024;31(5):e16229. doi:10.1111/ene.16229
Narayanaswami P, Sanders DB, Wolfe G, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology. 2021;96(3):114-122. doi:10.1212/WNL.0000000000011124
Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976-986. doi:10.1016/S1474-4422(17)30369-1
Muppidi S, Utsugisawa K, Benatar M, et al. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019;60(1):14-24. doi:10.1002/mus.26447
Mantegazza R, Wolfe GI, Muppidi S, et al. Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension. Neurology. 2021;96(4):e610-e618. doi:10.1212/WNL.0000000000011207
Siddiqi ZA, Nowak RJ, Mozaffar T, et al. Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study. Muscle Nerve. 2021;64(6):662-669. doi:10.1002/mus.27422
Vu TH, Mantegazza R, Annane D, et al. Long-Term Efficacy and Safety of Ravulizumab in Adults With Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open-Label Extension. Eur J Neurol. 2025;32(4):e70158. doi:10.1111/ene.70158
Howard JF Jr, Bresch S, Genge A, et al. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol. 2023;22(5):395-406. doi:10.1016/S1474-4422(23)00080-7
Sivadasan, A., & Bril, V. (2023). Clinical Efficacy and Safety of Efgartigimod for Treatment of Myasthenia Gravis. Immunotherapy, 15(8), 553–563. https://doi.org/10.2217/imt-2022-0298
Bril V, Drużdż A, Grosskreutz J, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023;22(5):383-394. doi:10.1016/S1474-4422(23)00077-7
Iorio R. Myasthenia gravis: the changing treatment landscape in the era of molecular therapies. Nat Rev Neurol. 2024;20(2):84-98. doi:10.1038/s41582-023-00916-w
Bril V, Drużdż A, Grosskreutz J, et al. Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open-label extension MG0004 study. J Neurol. 2025;272(4):275. Published 2025 Mar 19. doi:10.1007/s00415-025-12958-9
Granit V, Benatar M, Kurtoglu M, et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study. Lancet Neurol. 2023;22(7):578-590. doi:10.1016/S1474-4422(23)00194-1
Bryant A, Atkins H, Pringle CE, et al. Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell Transplantation. JAMA Neurol. 2016;73(6):652-658. doi:10.1001/jamaneurol.2016.0113
